Akèy › Limfòm folikilè › Texas
Etid klinik pou Limfòm folikilè nan Texas
35 etid pou Limfòm folikilè ap chèche patisipan nan sit nan Texas.
Vil nan Texas
Tèks ofisyèl etid la (Anglè)
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- NEXT Dallas, Irving
- NEXT Oncology, San Antonio
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT03460977Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Texas Children's Hospital, Houston
Ap rekriteEtid obsèvasyon
Laj 0 a 38 · Tout sèks · Mizajou Oct 1, 2026 · NCT06131801A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Research Site, Houston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT06542250A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Md Anderson Cancer Center, Houston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05006716A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Texas Oncology - DFW (Sammons CC), Dallas
- Baylor College of Medicine, Houston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07226843A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- University of Texas Southwestern, Dallas
- MD Anderson Cancer Center, Houston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07101328A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
- Baylor Scott & White Research Institute, Dallas
- The University of Texas MD Anderson Cancer Center, Houston
- South Texas Accelerated Research Therapeutics (START), San Antonio
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT05765812A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
- Research Site, Austin
- Research Site, Lubbock
- Research Site, Shenandoah
- ak 1 plis
Ap rekriteFaz 3
Laj 18 a 130 · Tout sèks · Mizajou Sep 21, 2026 · NCT06549595NEO100 and High-Grade Meningioma
- Baylor Scott and White, Dallas
Ap rekriteFaz 2
Laj 12 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT05023018Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
- Research Site, Austin
- Research Site, Houston
- Research Site, San Antonio
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06526793Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
- Texas Oncology, Dallas
Ap rekriteFaz 3
Laj 12 a 100 · Tout sèks · Mizajou Sep 11, 2026 · NCT06784752A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
- Center for Oncology and Blood Disorders, Houston
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06091254A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
- MD Anderson Cancer Center, Houston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT06043323A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234
- Research Site, San Antonio
Ap rekriteFaz 1Volontè an sante akeyi
Laj 18 a 85 · Tout sèks · Mizajou Sep 1, 2026 · NCT07546760Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma
- M D Anderson Cancer Center, Houston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 31, 2026 · NCT06108232SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- University of Texas Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
- University of Texas Health Mays Cancer Center, San Antonio
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT05303519Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Baylor University Medical Center, Dallas
- Texas Transplant Institute, San Antonio
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT05826535Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- University of Texas MD Anderson Cancer Center, Houston
Ap rekriteFaz 1/2
Laj 13 a 90 · Tout sèks · Mizajou Aug 6, 2026 · NCT06533579Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)
- Natera, Inc., Austin
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Aug 6, 2026 · NCT07750886A Study of APG-3288 in Relapsed/Refractory Blood Cancers
- The University of TX MD Anderson Cancer Center, Houston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 30, 2026 · NCT07424833Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury
- Memorial Hermann Hospital / UTHealth McGovern Medical School at Houston, Houston
- The University of Texas Health Science at San Antonio, San Antonio
Ap rekriteFaz 2
Laj 18 a 55 · Tout sèks · Mizajou Jul 15, 2026 · NCT05951777A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- MD Anderson Cancer Center, Houston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 2, 2026 · NCT05131022A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment
- Texas Liver Institute - American Research Corporation, San Antonio
- Pinnacle Clinical Research, San Antonio
Ap rekriteFaz 1
Laj 18 a 80 · Tout sèks · Mizajou Jun 16, 2026 · NCT07559474A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
- Texas Oncology - Central/South Texas, Austin
- Local Institution - 0212, Fort Worth
- Local Institution - 0230, San Antonio
- ak 1 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou May 20, 2026 · NCT06911502The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- University of Texas(UT) Southwestern-Children's Medical Center, Dallas
Ap rekriteFaz 1/2
Laj 12 a 95 · Tout sèks · Mizajou Apr 15, 2026 · NCT04329728A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- MD Anderson Cancer Center, Houston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Mar 20, 2026 · NCT04830137Study of SGR-1505 in Mature B-Cell Neoplasms
- University of Texas Southwestern, Dallas
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Feb 13, 2026 · NCT05544019Feasibility Study for the SIRA-1000, SIRA® RFA Electrosurgical Device as an Adjunct to Breast Conserving Surgery
- University of Texas Medical Branch at Galveston, TX, Galveston
Ap rekrite
Laj 50 ak plis · Fanm · Mizajou Feb 11, 2026 · NCT07206121Cognitive Screening Made Easy for PCPs - Administrative Supplement
- Family Wellness Clinic, Austin
- University of Texas Health Austin Primary Care Clinic, Austin
- UT Health San Antonio's Geriatrics and Supportive Care Clinic, San Antonio
Ap rekriteVolontè an sante akeyi
Laj 60 ak plis · Tout sèks · Mizajou Feb 5, 2026 · NCT06928298AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- Oncology Consultants, Houston
- University of Texas MD Anderson Cancer Center, Houston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Dec 10, 2025 · NCT05602363A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
- SCRI, San Antonio
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Nov 14, 2025 · NCT05643742SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Dallas
- Massive Bio SYNERGY-AI site, Houston
- Massive Bio SYNERGY-AI site, Temple
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- University of Texas Southwestern Medical Center, Dallas
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2025 · NCT05780034Phosphatidylethanol and Other Ethanol Consumption Markers
- University of North Texas, Denton
- University of Texas Health Science Center San Antonio, San Antonio
Ap rekriteVolontè an sante akeyi
Laj 21 ak plis · Tout sèks · Mizajou May 13, 2025 · NCT06747364Paper-Based and Smartphone-Based Memory Supports
- UT Health Austin Comprehensive Memory Center, Austin
- Baylor Scott & White Healthcare, Temple
- Baylor University, Waco
Ap rekrite
Laj 50 ak plis · Tout sèks · Mizajou Jul 9, 2024 · NCT06444841Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.